{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'IS AMENDED TO:', 'Clinical Research Contacts:', 'PPD', 'Clinical Science', ',', 'Astellas Pharma Global Development, Inc.', '1 Astellas Way', 'Northbrook, IL 60062', 'PPD', 'III List of Abbreviations and Definitions of Key Terms', 'List of Abbreviations', 'ADDED:', 'COE', 'Crossover Extension', 'IV Synopsis, Study Objectives', 'WAS:', 'Exploratory', 'To evaluate PFS in the next line of therapy (PFS2) of EV compared to chemotherapy', 'IS AMENDED TO:', 'Exploratory', 'To evaluate PFS as assessed by RECIST V1.1 by investigator review in the next line', 'of therapy (PFS2) in subjects treated withof EV compared to chemotherapy', '14 Sep 2020', 'Astellas', 'Page 138 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'V Flow Chart and Schedule of Assessments', 'Table 2 Pharmacokinetic, ATA, and biomarker blood sample collection timepoints - Arm A', 'WAS:', 'Blood', 'Study Day', 'Time', 'Window', 'Relative Time', 'PI', 'au', 'mia', 'ATA', 'Biomarkers', 'Subsequent Dosing Cycles', 'Day 1', 'Pre-dose', 'Within 24 hrs', 'START of infusion', 'XA', 'XA', 'XB', 'XC', 'XB', 'A. Pharmacokinetics and ATA: Pre-dose of cycle 3, 4 and every even numbered cycle there after', 'B. Cytokines and Immuno-phenotyping: Pre-dose cycles 3 and 4 only', 'C. cfDNA: Pre-dose every even numbered cycle (e.g., cycle 4, 6, etc.) only', 'IS AMENDED TO:', 'Cycles 3, 4, 6, 8 and 10', 'Day 1', 'Pre-dose', 'Within 24 hrs', 'START of infusion', 'XA', 'XA', 'XB', 'XC', 'XB', 'Subsequent Dosing Cycles', 'A. Pharmacokinetics and ATA: Pre-dose of cycle 3, 4, 6, 8 and 10 nd every numbered cycle there after', 'B. Cytokines and Immuno-phenotyping: Pre-dose cycles 3 and 4 only', 'C. cfDNA: Pre-dose every even numbered cycle up to 10 cycles (e.g., cycle 4, 6, 8, 10etc.) only', 'V Flow Chart and Schedule of Assessments', 'Biomarker blood sample collection timepoints - Arm B', 'WAS:', 'A. cfDNA: Pre-dose every even numbered cycle (e.g., cycle 4, 6, etc.) only', 'IS AMENDED TO:', 'A. cfDNA: Pre-dose every even numbered cycle up to 10 cycles (e.g., cycle 4, 6, etc-8, 10-) only', '14 Sep 2020', 'Astellas', 'Page 139 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'IV Synopsis, Study Design Overview and 2 Study Objective(s), Design and Enppoints', '2.2.1 Study Design', 'WAS:', 'Subjects in Arm A will receive EV on Days 1, 8 and 15 of each 28-day cycle. Subjects in', 'arm B will receive either docetaxel, paclitaxel or vinflunine (as decided by the investigator', 'prior to randomization: vinflunine is a choice of comparator only in countries where it is', 'approved for urothelial cancer) on Day 1 of every 21 day cycle.', 'No on-study crossover will be allowed. This study will consist of 3 phases: screening,', 'treatment and follow-up.', 'IS AMENDED TO:', 'Subjects in Arm A will receive EV on Days 1, 8 and 15 of each 28-day cycle. Subjects in', 'arm B will receive either docetaxel, paclitaxel or vinflunine (as decided by the investigator', 'prior to randomization: vinflunine is a choice of comparator only in countries where it is', 'approved for urothelial cancer) on Day 1 of every 21 day cycle.', 'No on-study crossover will be allowed other than as allowed in Appendix 12.10 This', 'study will consist of 3 phases: screening, treatment and follow-up', '7 Statistical Methodology', '7.2.3 Response Evaluable Set', 'WAS:', 'The response evaluable set (RES) is defined as all subjects in FAS and with measurable', 'disease at baseline and had at least 6 months follow up since randomization. RES will be', 'used for primary efficacy analysis of response related endpoints, e.g., ORR and DCR.', 'IS AMENDED TO:', 'The response evaluable set (RES) is defined as all subjects in FAS and with measurable', 'disease (per RECIST V1.1) at baseline and had at least 6 months follow up since', 'randomization. RES will be used for primary efficacy analysis of response related', 'endpoints, e.g., ORR and DCR.', '7 Statistical Methodology', '7.4 Analysis of Efficacy', 'WAS:', 'family-wise type I error rate for this study is strongly controlled at 2.5% (one-sided) that', 'allows the study to declare positive on primary endpoint os on the FAS population. OS', 'will be formally tested at both interim analysis and final analysis. At either interim or final', 'analysis, the formal hypothesis tests on the selected secondary endpoints including PFS1,', 'ORR and DCR, will be performed hierarchically (per the order of PFS1-> ORR->DCR)', 'only when the OS analysis is rejected. The details about the significance levels at interim', 'analysis and final analysis for each efficacy endpoints (OS, PFS1, ORR and DCR) is', 'specified in SAP.', '14 Sep 2020', 'Astellas', 'Page 140 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}